Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity combo drug tested for safety in japanese adults

NCT ID NCT06297616

First seen Jan 20, 2026 · Last updated Apr 29, 2026 · Updated 13 times

Summary

This study looked at the safety and side effects of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Participants received multiple doses over several weeks, and researchers monitored for serious side effects and how the drugs affected body weight. The goal was to gather early safety data, not to cure obesity, so ongoing weight management would still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hakata Clinic

    Fukuoka, 812-0025, Japan

  • P-One Clinic

    Hachiōji, Tokyo, 192-0071, Japan

  • Sumida Hospital

    Sumida-ku, Tokyo, 130-0004, Japan

Conditions

Explore the condition pages connected to this study.